|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mittal S and El-Serag HB: Epidemiology of
hepatocellular carcinoma: Consider the population. J Clin
Gastroenterol. 47 Suppl:S2–S6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pinter M, Trauner M, Peck-Radosavljevic M
and Sieghart W: Cancer and liver cirrhosis: Implications on
prognosis and management. ESMO Open. 1:e0000422016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kanda T, Ogasawara S, Chiba T, Haga Y,
Omata M and Yokosuka O: Current management of patients with
hepatocellular carcinoma. World J Hepatol. 7:1913–1920. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chromik AM, Daigeler A, Bulut D, Flier A,
May C, Harati K, Roschinsky J, Sülberg D, Ritter PR, Mittelkötter
U, et al: Comparative analysis of cell death induction by
Taurolidine in different malignant human cancer cell lines. J Exp
Clin Cancer Res. 29:212010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stendel R, Stoltenburgdidinger G, Al Keikh
CL, Wattrodt M and Brock M: The effect of taurolidine on brain
tumor cells. Anticancer Res. 22:809–814. 2002.PubMed/NCBI
|
|
7
|
Stendel R, Biefer HR, Dékány GM, Kubota H,
Münz C, Wang S, Mohler H, Yonekawa Y and Frei K: The antibacterial
substance taurolidine exhibits anti-neoplastic action based on a
mixed type of programmed cell death. Autophagy. 5:194–210. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Braumann C, Jacobi CA, Rogalla S,
Menenakos C, Fuehrer K, Trefzer U and Hofmann M: The tumor
suppressive reagent taurolidine inhibits growth of malignant
melanoma-a mouse model. J Surg Res. 143:372–378. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun BS, Wang JH, Liu LL, Gong SL and
Redmond HP: Taurolidine induces apoptosis of murine melanoma cells
in vitro and in vivo by modulation of the Bcl-2 family proteins. J
Surg Oncol. 96:241–248. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Opitz I, Sigrist B, Hillinger S, Lardinois
D, Stahel R, Weder W and Hopkins-Donaldson S: Taurolidine and
povidone-iodine induce different types of cell death in malignant
pleural mesothelioma. Lung Cancer. 56:327–336. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aceto N, Bertino P, Barbone D, Tassi G,
Manzo L, Porta C, Mutti L and Gaudino G: Taurolidine and oxidative
stress: A rationale for local treatment of mesothelioma. Eur Respir
J. 34:1399–1407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Braumann C, Schoenbeck M, Menenakos C,
Kilian M and Jacobi CA: Effects of increasing doses of a bolus
injection and an intravenous long-term therapy of taurolidine on
subcutaneous (metastatic) tumor growth in rats. Clin Exp
Metastasis. 22:77–83. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chromik AM, Daigeler A, Hilgert C, Bulut
D, Geisler A, Liu V, Otte JM, Uhl W and Mittelkötter U: Synergistic
effects in apoptosis induction by taurolidine and TRAIL in HCT-15
colon carcinoma cells. J Invest Surg. 20:339–348. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Daigeler A, Chromik AM, Geisler A, Bulut
D, Hilgert C, Krieg A, Klein-Hitpass L, Lehnhardt M, Uhl W and
Mittelkötter U: Synergistic apoptotic effects of taurolidine and
TRAIL on squamous carcinoma cells of the esophagus. Int J Oncol.
32:1205–1220. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Walters DK, Muff R, Langsam B, Gruber P,
Born W and Fuchs B: Taurolidine: A novel anti-neoplastic agent
induces apoptosis of osteosarcoma cell lines. Invest New Drugs.
25:305–312. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Daigeler A, Brenzel C, Bulut D, Geisler A,
Hilgert C, Lehnhardt M, Steinau HU, Flier A, Steinstraesser L,
Klein-Hitpass L, et al: TRAIL and Taurolidine induce apoptosis and
decrease proliferation in human fibrosarcoma. J Exp Clin Cancer
Res. 27:822008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chidambaram NV, Angell JE, Ling W, Hofmann
ER and Kalvakolanu DV: Chromosomal localization of human GRIM-19, a
novel IFN-beta and retinoic acid-activated regulator of cell death.
J Interferon Cytokine Res. 20:661–665. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Y, Lu H, Liu Q, Huang G, Lim CP,
Zhang L, Hao A and Cao X: Function of GRIM-19, a mitochondrial
respiratory chain complex I protein, in innate immunity. J Biol
Chem. 287:27227–27235. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li F, Ren W, Zhao Y, Fu Z, Ji Y, Zhu Y and
Qin C: Downregulation of GRIM-19 is associated with hyperactivation
of p-STAT3 in hepatocellular carcinoma. Med Oncol. 29:3046–3054.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao J, Nie W, Li W, Zhou X, Sun H, Zhu J,
Chen J and Peng J: Interferon-β combined with all-trans retinoic
acid supresses proliferation and promote apoptosis by inhibiting
JAK2/STAT3 pathway in HepG2 human hepatocellular carcinoma cells.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 32:901–905. 2016.(In Chinese).
PubMed/NCBI
|
|
21
|
Gong L, Greenberg HE, Perhach JL, Waldman
SA and Kraft WK: The pharmacokinetics of taurolidine metabolites in
healthy volunteers. J Clin Pharmacol. 47:697–703. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Braumann C, Winkler G, Rogalla P,
Menenakos C and Jacobi CA: Prevention of disease progression in a
patient with a gastric cancer-re-recurrence. Outcome after
intravenous treatment with the novel antineoplastic agent
taurolidine. Report of a case. World J Surg Oncol. 4:342006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stendel R, Picht T, Schilling A,
Heidenreich J, Loddenkemper C, Jänisch W and Brock M: Treatment of
glioblastoma with intravenous taurolidine. First clinical
experience. Anticancer Res. 24:1143–1147. 2004.PubMed/NCBI
|
|
24
|
Stendel R, Scheurer L, Schlatterer K,
Stalder U, Pfirrmann RW, Fiss I, Möhler H and Bigler L:
Pharmacokinetics of taurolidine following repeated intravenous
infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame
and taurinamide in glioblastoma patients. Clin Pharmacokinet.
46:513–524. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Darnowski JW, Goulette FA, Cousens LP,
Chatterjee D and Calabresi P: Mechanistic and antineoplastic
evaluation of taurolidine in the DU145 model of human prostate
cancer. Cancer Chemother Pharmacol. 54:249–258. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Han Z, Ribbizi I, Pantazis P, Wyche J,
Darnowski J and Calabresi P: The antibacterial drug taurolidine
induces apoptosis by a mitochondrial cytochrome c-dependent
mechanism. Anticancer Res. 22:1959–1964. 2002.PubMed/NCBI
|
|
27
|
Rodak R, Kubota H, Ishihara H, Eugster HP,
Könü D, Möhler H, Yonekawa Y and Frei K: Induction of reactive
oxygen intermediates-dependent programmed cell death in human
malignant ex vivo glioma cells and inhibition of the vascular
endothelial growth factor production by taurolidine. J Neurosurg.
102:1055–1068. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stendel R, Scheurer L,
Stoltenburg-Didinger G, Brock M and Möhler H: Enhancement of
Fas-ligand-mediated programmed cell death by taurolidine.
Anticancer Res. 23:2309–2314. 2003.PubMed/NCBI
|
|
29
|
Kolligs FT, Nieman MT, Winer I, Hu G, Van
Mater D, Feng Y, Smith IM, Wu R, Zhai Y, Cho KR, et al: ITF-2, a
downstream target of the Wnt/TCF pathway, is activated in human
cancers with beta-catenin defects and promotes neoplastic
transformation. Cancer Cell. 1:145–155. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ottaviano AJ, Sun L, Ananthanarayanan V
and Munshi HG: Extracellular matrix-mediated membrane-type 1 matrix
metalloproteinase expression in pancreatic ductal cells is
regulated by transforming growth factor-beta1. Cancer Res.
66:7032–7040. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wei D, Le X, Zheng L, Wang L, Frey JA, Gao
AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL and Xie K: Stat3
activation regulates the expression of vascular endothelial growth
factor and human pancreatic cancer angiogenesis and metastasis.
Oncogene. 22:319–329. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jacobi CA, Menenakos C and Braumann C:
Taurolidine-a new drug with anti-tumor and anti-angiogenic effects.
Anticancer Drugs. 16:917–921. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mccourt M, Wang JH, Sookhai S and Redmond
HP: Taurolidine inhibits tumor cell growth in vitro and in vivo.
Ann Surg Oncol. 7:685–691. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Petrovic L, Schlegel KA, Ries J, Park J,
Diebel E, Schultze-Mosgau S and Wiltfang J: In vitro effect of
taurolidine on squamous cell carcinoma in the oral cavity. Mund
Kiefer Gesichtschir. 7:102–107. 2003.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gallagher KA, Liu ZJ, Xiao M, Chen H,
Goldstein LJ, Buerk DG, Nedeau A, Thom SR and Velazquez OC:
Diabetic impairments in NO-mediated endothelial progenitor cell
mobilization and homing are reversed by hyperoxia and SDF-1. J Clin
Invest. 117:1249–1259. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Calabresi P, Goulette FA and Darnowski JW:
Taurolidine: Cytotoxic and mechanistic evaluation of a novel
antineoplastic agent. Cancer Res. 61:6816–6821. 2001.PubMed/NCBI
|
|
38
|
Braumann C, Henke W, Jacobi CA and Dubiel
W: The tumor-suppressive reagent taurolidine is an inhibitor of
protein biosynthesis. Int J Cancer. 112:225–230. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Neary PM, Hallihan P, Wang JH, Pfirrmann
RW, Bouchier-Hayes DJ and Redmond HP: The evolving role of
taurolidine in cancer therapy. Ann Surg Oncol. 17:1135–1143. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Haura EB, Turkson J and Jove R: Mechanisms
of disease: Insights into the emerging role of signal transducers
and activators of transcription in cancer. Nat Clin Pract Oncol.
2:315–324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Oltvai ZN, Milliman CL and Korsmeyer SJ:
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that
accelerates programed cell death. Cell. 74:609–619. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Korsmeyer SJ, Shutter JR, Veis DJ, Merry
DE and Oltvai ZN: Bcl-2/Bax: A rheostat that regulates an
anti-oxidant pathway and cell death. Semin Cancer Biol. 4:327–332.
1993.PubMed/NCBI
|
|
43
|
Tsukahara S, Yamamoto S, Tin-Tin-Win-Shwe,
Ahmed S, Kunugita N, Arashidani K and Fujimaki H: Inhalation of
low-level formaldehyde increases the Bcl-2/Bax expression ratio in
the hippocampus of immunologically sensitized mice.
Neuroimmunomodulation. 13:63–68. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Walensky LD: BCL-2 in the crosshairs:
Tipping the balance of life and death. Cell Death Differ.
13:1339–1350. 2006. View Article : Google Scholar : PubMed/NCBI
|
